Search Result

Results for "

Tumour

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (4) Acyltransferase (1) ADC Payload (1) Adrenergic Receptor (1) Akt (1) AMPK (3) Antibiotic (10) Apoptosis (43) Arp2/3 Complex (1) Aryl Hydrocarbon Receptor (1) Autophagy (9) Bacterial (17) Bcl-2 Family (1) Biochemical Assay Reagents (2) BRK (1) c-Fms (1) Calcium Channel (1) Carboxylesterase (CES) (2) Casein Kinase (1) CD3 (1) CD47 (3) CDK (7) Cholinesterase (ChE) (3) Complement System (1) Cytochrome P450 (6) DNA Alkylator/Crosslinker (6) DNA/RNA Synthesis (9) Dopamine Receptor (3) Drug Derivative (2) Drug Intermediate (1) E1/E2/E3 Enzyme (1) EBV (1) EGFR (9) Endogenous Metabolite (13) Enolase (1) Epigenetic Reader Domain (2) Estrogen Receptor/ERR (2) FAK (2) FAP (1) FGFR (2) FLT3 (1) Fluorescent Dye (3) Fungal (6) GLUT (1) Glutaminase (2) Glycosyltransferase (1) HBV (1) HDAC (6) Histamine Receptor (2) Histone Acetyltransferase (1) Histone Methyltransferase (1) HIV (3) HSP (3) HSV (1) IAP (2) IGF-1R (2) IKK (1) Influenza Virus (2) Interleukin Related (4) Isotope-Labeled Compounds (7) JAK (1) JNK (1) LAG-3 (2) Ligands for E3 Ligase (1) MAP3K (1) MAP4K (1) MDM-2/p53 (2) Microtubule/Tubulin (2) Mitochondrial Metabolism (5) Mitophagy (4) Mitosis (1) MMP (5) Molecular Glues (1) NAMPT (2) NEDD8-activating Enzyme (3) NF-κB (4) NO Synthase (3) Nucleoside Antimetabolite/Analog (2) P2X Receptor (1) p38 MAPK (2) PAK (1) Parasite (1) PD-1/PD-L1 (15) Peptide-Drug Conjugates (PDCs) (1) Phosphatase (2) PI3K (2) PKC (2) PROTACs (5) PSMA (1) Quinone Reductase (1) Radionuclide-Drug Conjugates (RDCs) (1) Ras (1) Reactive Oxygen Species (ROS) (6) Reference Standards (11) ROS Kinase (1) SARS-CoV (2) Sodium Channel (7) SOS1 (1) Src (3) STAT (2) STING (1) Syk (1) TGF-beta/Smad (2) TGF-β Receptor (5) TNF Receptor (6) Toll-like Receptor (TLR) (1) Topoisomerase (3) Transmembrane Glycoprotein (6) TRP Channel (1) VEGFR (2) Virus Protease (7) YAP (1)
By Research Areas:	Cancer (209) Cardiovascular Disease (6) Endocrinology (6) Infection (23) Inflammation/Immunology (26) Metabolic Disease (9) Neurological Disease (16)
Click Chemistry:	Azide (1) Alkynes (2)
Oligonucleotides:	Antisense Oligonucleotides (1)

213

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17449

Fosbretabulin disodium CA 4DP; CA 4P; Combretastatin A4 disodium phosphate	Microtubule/Tubulin Apoptosis	Cancer
Fosbretabulin disodium (CA 4DP) is a tubulin destabilizing agent. Fosbretabulin disodium is the Combretastatin A4 proagent that selectively targets endothelial cells, induces regression of nascent tumour neovessels, reduces tumour blood flow and causes central tumour necrosis .

HY-108669

AZ10606120 dihydrochloride 2 Publications Verification	P2X Receptor	Neurological Disease Cancer
AZ10606120 dihydrochloride is a selective, high affinity antagonist for P2X7 receptor (P2X7R) at human and rat with an IC₅₀ of about 10 nM. AZ10606120 dihydrochloride is little or no effect at other P2XR subtypes. AZ10606120 dihydrochloride has anti-depressant effects and reduces tumour growth .

HY-46568

CDK7/12-IN-1	CDK	Cancer
CDK7/12-IN-1 is a selective CDK7/12 inhibitor with IC₅₀s of 3 and 277 nM for CDK7 and CDK 12, respectively. CDK7 and CDK12 inhibition is an effective strategy to inhibit tumour growth .

HY-P5472

Tumour-associated MUC1 epitope	Transmembrane Glycoprotein	Others
Tumour-associated MUC1 epitope is a biological active peptide. (This sequence is the hallmark of MUC1 mucin. MUC1 is a highly glycosylated type I transmembrane glycoprotein with a unique extracellular domain consisting of a variable number of tandem repeats (VNTR) of this 20 amino acid peptide. It is overexpressed on the cell surface of many human adenocarcinomas and hematological malignancies, including multiple myeloma and B-cell lymphoma, making MUC1 broadly applicable target for immunotherapeutic strategies.)

HY-P991349

GNR-051	PD-1/PD-L1	Cancer
GNR-051 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. GNR-051 can be used in Solid tumours research .

HY-P99565

Tengonermin ARENEGYR; NGR-TNF; NGR-hTNF	TNF Receptor	Cancer
Tengonermin (ARENEGYR) is a vascular-targeting agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. Tengonermin increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment .

HY-P991457

AVE1642	IGF-1R	Cancer
AVE1642 is a human IgG monoclonal antibody (mAb) targeting CD221/IGF1R. AVE1642 delays growth of tumour xenografts and prolongs the survival of tumour-bearing nude mice. AVE1642 can be used in advanced solid tumours research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-139179

STING agonist-14	STING	Infection Cancer
STING agonist-14 (compound 12b) is a potent STING agonist that is efficacious across species. STING agonist-14 could activate the pathway by directly binding human STING. STING agonist-14 can be used for the research of tumours or viral infections .

HY-P991348

BAT-1306	PD-1/PD-L1	Cancer
BAT-1306 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. BAT-1306 can be used in Colorectal cancer and Solid tumours research .

HY-156675

Plecstatin-1	Others	Cancer
Plecstatin-1 is a potent organoruthenium anti-cancer agent . Plecstatin-1 selectively targets plectin (a scaffold protein and cytolinker) in tumour spheroids .

HY-172320

BMS-986238	PD-1/PD-L1	Cancer
BMS-986238, a second-generation macrocyclic peptide, is a potent PD-L1 inhibitor. BMS-986238 has the potential for the study of solid tumours and lymphomas (cancer of the lymphatic system) .

HY-P991469

AMG-211 MEDI-565	Transmembrane Glycoprotein	Cancer
AMG-211 (MEDI-565) is a human monoclonal antibody (mAb) targeting CEACAM5/CEA/CD66e. AMG-211 can be used in Gastrointestinal cancer and Solid tumours research .

HY-W013514

2-Acetamidofluorene	DNA/RNA Synthesis	Cancer
2-Acetamidofluorene is a potent carcinogenan. 2-Acetamidofluorene is can be used fot induction of hepatocellular carcinoma (HCC) and multiple primary tumours .

HY-B0448

Phenytoin 5 Publications Verification 5,5-Diphenylhydantoin	Sodium Channel Virus Protease	Neurological Disease Cancer
Phenytoin (5,5-Diphenylhydantoin) is a potent Voltage-gated Na ⁺ channels (VGSCs) blocker. Phenytoin has antiepileptic activity and reduces breast tumour growth and metastasis in mice .

HY-B0448A

Phenytoin sodium 5 Publications Verification 5,5-Diphenylhydantoin sodium salt	Sodium Channel Virus Protease	Neurological Disease Cancer
Phenytoin sodium (5,5-Diphenylhydantoin sodium salt) is a potent Voltage-gated Na ⁺ channels (VGSCs) blocker. Phenytoin has antiepileptic activity and reduces breast tumour growth and metastasis in mice .

HY-128470

Mitoquidone GR-30921	Drug Derivative	Cancer
Mitoquidone (GR-30921) is is the first member of a group of pentacyclic pyrroloquinones. Mitoquidone shows good activity in a range of experimental solid tumour models. Mitoquidone can be used for the research of anti-cancer .

HY-P991344

AMP-224	PD-1/PD-L1	Cancer
AMP-224 is a fusion protein targeting PD-L2. AMP-224 specifically binds to PD-1 T cells (chronically stimulated/exhausted T cells). AMP-224 can be used in Colorectal cancer and Solid tumours research .

HY-14247B

Fadrozole hydrochloride hemihydrate CGS 16949A hemihydrate; (Rac)-FAD286 hydrochloride hemihydrate	Cytochrome P450	Endocrinology Cancer
Fadrozole hydrochloride hemihydrate is an orally active, potent, selective and nonsteroidal aromatase inhibitor, with an IC₅₀ of 6.4 nM. Fadrozole hydrochloride hemihydrate inhibits the production of estrogen and progesterone, with IC₅₀ values of 0.03 and 120 μM. Fadrozole hydrochloride hemihydrate shows prevention of spontaneous tumours. Fadrozole hydrochloride hemihydrate can be used for the research of estrogen-dependent disease and cancer .

HY-139453A

LP-284	DNA Alkylator/Crosslinker	Cancer
LP-284 is a potent DNA alkylating agent that kills solid tumours. LP-284 can be used in the studies of hematologic cancers with compromised DNA repair, such as mantle cell lymphoma (MCL) .

HY-108345

Bleomycin	Antibiotic	Cancer
Bleomycin is a glycopeptide antibiotic. Bleomycin has potent antitumour activities against a range of lymphomas, head and neck cancers and germ-cell tumours. Bleomycin can be used for the research of cancer and chemotherapy .

HY-B0448R

Phenytoin (Standard) 5,5-Diphenylhydantoin (Standard)	Reference Standards Sodium Channel Virus Protease	Neurological Disease Cancer
Phenytoin (Standard) is the analytical standard of Phenytoin. This product is intended for research and analytical applications. Phenytoin (5,5-Diphenylhydantoin) is a potent Voltage-gated Na ⁺ channels (VGSCs) blocker. Phenytoin has antiepileptic activity and reduces breast tumour growth and metastasis in mice .

HY-B0448AR

Phenytoin sodium (Standard) 5,5-Diphenylhydantoin sodium salt (Standard)	Reference Standards Sodium Channel Virus Protease	Neurological Disease Cancer
Phenytoin (sodium) (Standard) is the analytical standard of Phenytoin (sodium). This product is intended for research and analytical applications. Phenytoin sodium (5,5-Diphenylhydantoin sodium salt) is a potent Voltage-gated Na+ channels (VGSCs) blocker. Phenytoin has antiepileptic activity and reduces breast tumour growth and metastasis in mice .

HY-P991391

COM902	Transmembrane Glycoprotein	Cancer
COM902 is a human IgG4 monoclonal antibody (mAb) targeting TIGIT. COM902 enhances anti-tumor immune responses. COM902 can be used in Multiple myeloma, Solid tumours and Colorectal cancer research. Recommended isotype control: IgG4-lambda .

HY-P99450

Avdoralimab IPH 5401; Anti-C5aR1 mAb	Complement System	Inflammation/Immunology Cancer
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .

HY-P991352

SG-001	PD-1/PD-L1	Cancer
SG-001 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. SG-001 can be used in Cervical cancer, Colorectal cancer, Solid tumours and Biliary cancer research .

HY-15940

5(6)-Carboxyfluorescein 3 Publications Verification 5(6)-FAM; 5-(and-6)-Carboxyfluorescein mixed isomers	Fluorescent Dye	Cancer
5(6)-Carboxyfluorescein (5(6)-FAM) is an amine-reactive pH-sensitive green fluorescent probe. 5(6)-Carboxyfluorescein (5(6)-FAM) can be used to label proteins, peptides and nucleotides. 5(6)-Carboxyfluorescein can be used for the detection of tumour areas in vivo .

HY-100983

Protein kinase inhibitor H-7 dihydrochloride	PKC	Cancer
Protein kinase inhibitor H-7 dihydrochloride is a potent PKC (protein kinase C) inhibitor. At 100 μM, Protein kinase inhibitor H-7 dihydrochloride completely inhibits both TPA (skin tumour promoter, 12-O-tetradecanoylphorbol-13-acetate) and phospholipase C-induced ODC (ornithine decarboxylase) .

HY-148278

BI-0474	SOS1 Ras	Cancer
BI-0474 is a potent KRAS ^G12C inhibitor with an IC₅₀ value of 7.0 nM for the GDP-KRAS::SOS1 protein-protein interaction. BI-0474 exhibits good anti-proliferative activity against NCI-H358 cells carrying the G12C mutation. BI-0474 also shows good anti-tumour activity in non-small cell lung cancer xenograft models .

HY-124178

(R)-Levrazoxane (R)-ICRF 186	Drug Intermediate	Metabolic Disease
(R)-Levrazoxane ((R)-ICRF 186) is enzymatically hydrolysed to one-ring open intermediates by dihydropyrimidine amidohydrolase (DPHase), which is present in the liver and kidney. The radiosensitizing efficiency of (R)-Levrazoxane towards EMT6 mouse mammary tumour cells is greater than that of Dexrazoxane (HY-B0581). (R)-Levrazoxane is promising for research of liver and kidney related diseases .

HY-176060

Platelet aggregation-IN-3	Histamine Receptor Adrenergic Receptor 5-HT Receptor	Cardiovascular Disease Cancer
Platelet aggregation-IN-3 (Compound 5) is a ligand for H₂ histamine receptors, α₂(A,C)-adrenergic receptors (α₂-AR), and 5-HT₂(B,C) serotonin receptors. Platelet aggregation-IN-3 can inhibit platelet aggregation induced by ADP and collagen and can also modulate tumour cell-induced platelet aggregation (TCIPA). Platelet aggregation-IN-3 is promising for research of antiplatelet therapy in cardiovascular diseases and the prevention of cancer-related thrombosis and tumour metastasis .

HY-150791

FLDP-5	Reactive Oxygen Species (ROS) DNA/RNA Synthesis	Cancer
FLDP-5 is a blood-brain barrier (BBB) penetrant curcuminoid analogues. FLDP-5 can induce production of ROS (Reactive Oxygen Species), DNA damage and cell cycle S phase arrest. FLDP-5 exhibits highly potent tumour-suppressive effects with anti-proliferative and anti-migratory activities on LN-18 cells .

HY-143874

HER2-IN-7	EGFR	Cancer
HER2-IN-7 is a potent inhibitor of HER2. Deregulation of ErbB family signalling modulates proliferation, invasion, metastasis, angiogenesis, and tumour cell survival. HER2-IN-7 has the potential for the research of diseases associated ErbBs (especially HER2), including cancer (extracted from patent WO2019214634A1, compound 23) .

HY-152219

CLK1-IN-2	CDK	Infection Cancer
CLK1-IN-2 is metabolically stable Clk1 inhibitor. CLK1-IN-2 has selectivity for Clk1 with an IC₅₀ value of 1.7 nM. CLK1-IN-2 can be used for the research of tumour, Duchenne's muscular dystrophy and viral infections such as HIV-1 and influenza .

HY-151379

EM127	Histone Methyltransferase	Cancer
EM127 (compound 11c) is a SMYD3 covalent inhibitor with high selectivity, high affinity (K_D=13 μM) and site-specificity. EM127 effectively inhibits ERK1/2 phosphorylation and reduces transcriptional regulation of SMYD3 target genes. EM127 effectively and prolongedly impairs methyltransferase activity. EM127 can be used in cancer research, particularly in SMYD3 positive tumours .

HY-151281

ALK5-IN-31	TGF-β Receptor	Cancer
ALK5-IN-31 (compound Ex-08) is a selective ALK-5 inhibitor (IC₅₀≤10 nM), inhibits TGF-β-induced SMAD signaling. ALK5-IN-31 has the potential to inhibit growth of tumour in vivo. ALK5-IN-31 can be used in study of proliferative diseases such as cancer, fibrotic diseases, and systemic sclerosis .

HY-151275

ALK5-IN-28	TGF-β Receptor TGF-beta/Smad	Cancer
ALK5-IN-28 (compound Ex-05) is a selective ALK-5 inhibitor (IC₅₀≤10 nM), inhibits TGF-β-induced SMAD signaling. ALK5-IN-28 has the potential to inhibit growth of tumour in vivo. ALK5-IN-28 can be used in study of proliferative diseases such as cancer, fibrotic diseases, and systemic sclerosis .

HY-151282

ALK5-IN-32	TGF-β Receptor TGF-beta/Smad	Cancer
ALK5-IN-32 (compound EX-09) is a selective ALK-5 inhibitor (10 nM<IC₅₀<100 nM), inhibits TGF-β-induced SMAD signaling. ALK5-IN-32 has the potential to inhibit growth of tumour in vivo. ALK5-IN-32 can be used in study of proliferative diseases such as cancer, fibrotic diseases, and systemic sclerosis .

HY-100983R

Protein kinase inhibitor H-7 dihydrochloride (Standard)	Reference Standards PKC	Cancer
Protein kinase inhibitor H-7 (dihydrochloride) (Standard) is the analytical standard of Protein kinase inhibitor H-7 (dihydrochloride). This product is intended for research and analytical applications. Protein kinase inhibitor H-7 dihydrochloride is a potent PKC (protein kinase C) inhibitor. At 100 μM, Protein kinase inhibitor H-7 dihydrochloride completely inhibits both TPA (skin tumour promoter, 12-O-tetradecanoylphorbol-13-acetate) and phospholipase C-induced ODC (ornithine decarboxylase) .

HY-124904

LY-195448	Endogenous Metabolite	Cancer
LY-195448 is a phenethanolamine that exhibits anti-tumour activity across various murine tumour models .

HY-13543

Tretazicar CB 1954	Quinone Reductase DNA Alkylator/Crosslinker	Cancer
Tretazicar (CB 1954), an antitumor proagent, is highly selective against the Walker 256 rat tumour line. Tretazicar is enzymatically activated to generate a bifunctional agent, which can form DNA-DNA interstrand cross-links. Tretazicar in rat cells involves the reduction of its 4-nitro group to a 4-hydroxylamine by the enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1) .

HY-13432

Nanatinostat 2 Publications Verification CHR-3996	HDAC Apoptosis	Cancer
Nanatinostat (CHR-3996) is a potent, class I selective and orally active HDAC inhibitor with IC₅₀s of 3 nM, 4 nM, and 7 nM for HDAC1, HDAC2, and HDAC3, respectively. Nanatinostat has low activity against HDAC5 (IC₅₀ of 200 nM) and HDAC6 (IC₅₀ of 2100 nM). Nanatinostat induces apoptosis in myeloma cells. Nanatinostat has potent anticancer effects, such as myeloma, advanced solid tumours and colorectal cancer .

HY-13543R

Tretazicar (Standard)	DNA Alkylator/Crosslinker	Cancer
Tretazicar (Standard) is the analytical standard of Tretazicar. This product is intended for research and analytical applications. Tretazicar (CB 1954), an antitumor proagent, is highly selective against the Walker 256 rat tumour line. Tretazicar is enzymatically activated to generate a bifunctional agent, which can form DNA-DNA interstrand cross-links. Tretazicar in rat cells involves the reduction of its 4-nitro group to a 4-hydroxylamine by the enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1) .

HY-13432A

Nanatinostat TFA CHR-3996 TFA	HDAC Apoptosis	Cancer
Nanatinostat (CHR-3996) TFA is a potent, class I selective and orally active HDAC inhibitor with IC₅₀s of 3 nM, 4 nM, and 7 nM for HDAC1, HDAC2, and HDAC3, respectively. Nanatinostat TFA has low activity against HDAC5 (IC₅₀ of 200 nM) and HDAC6 (IC₅₀ of 2100 nM). Nanatinostat TFA induces apoptosis in myeloma cells. Nanatinostat TFA has potent anticancer effects, such as myeloma, advanced solid tumours and colorectal cancer .

HY-12708

Chlorpromazine 80+ Cited Publications	Dopamine Receptor Cytochrome P450 Autophagy 5-HT Receptor	Cardiovascular Disease Neurological Disease Cancer
Chlorpromazine is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT_2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine also blocks hNa_v1.7 channels (IC₅₀=25.9 μM; concentration-dependent) and HERG potassium channels (IC₅₀=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine also can inhibit clathrin-mediated endocytosis .

HY-B0407A

Chlorpromazine hydrochloride 80+ Cited Publications	Dopamine Receptor Autophagy Cytochrome P450 5-HT Receptor	Cardiovascular Disease Neurological Disease Cancer
Chlorpromazine hydrochloride is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT_2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine hydrochloride exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine hydrochloride also blocks hNa_v1.7 channels (IC₅₀=25.9 μM; concentration-dependent) and HERG potassium channels (IC₅₀=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine hydrochloride also can inhibit clathrin-mediated endocytosis .

HY-16215

Mipsagargin G-202	Peptide-Drug Conjugates (PDCs) PSMA Calcium Channel	Cancer
Mipsagargin (G-202) is a novel thapsigargin-based targeted proagent consisting of a prostate-specific membrane antigen (PSMA)-specific peptide coupled to an analog of the potent sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump inhibitor Thapsigargin (HY-13433). Mipsagargin is activated by PSMA-mediated cleavage of an inert masking peptide. Mipsagargin has the potential for refractory, advanced or metastatic solid tumours research .

HY-16498

Tigapotide PCK-3145	Apoptosis	Cancer
Tigapotide (PCK-3145) is an anti-tumour peptide that reduces the development of skeletal metastases associated with prostate cancer. Tigapotide induces apoptosis and reduces tumour parathyroid hormone-related peptide (PTHrP) levels .

HY-B0407AR

Chlorpromazine hydrochloride (Standard)	Reference Standards Dopamine Receptor Autophagy Cytochrome P450 5-HT Receptor	Cardiovascular Disease Neurological Disease Cancer
Chlorpromazine (hydrochloride) (Standard) is the analytical standard of Chlorpromazine (hydrochloride). This product is intended for research and analytical applications. Chlorpromazine hydrochloride is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine hydrochloride exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine hydrochloride also blocks hNav1.7 channels (IC50=25.9 μM; concentration-dependent) and HERG potassium channels (IC50=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine hydrochloride also can inhibit clathrin-mediated endocytosis .

HY-136641

NOTA-FAPI	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
NOTA-FAPI is a fibroblast activation protein (FAP) inhibitor. NOTA-FAPI can be used as a probe for FAP-targeted tumour imaging. NOTA-FAPI has good tumour detection efficacy and excellent imaging quality .

HY-175003

HV1-IN-2	Others	Cancer
HV1-IN-2 (Compound 14c) is a human voltage-gated proton channel (HV1) inhibitor with an IC₅₀ of 2.14 μM. HV1-IN-2 has a potent anticancer activity with significant antiproliferative effects against THP-1 and MCF-7 cells. HV1-IN-2 can be used for cancers research, such as colorectal tumours, leukaemia, and breast cancer .

Cat. No.	Product Name	Type

HY-15940

5(6)-Carboxyfluorescein 3 Publications Verification 5(6)-FAM; 5-(and-6)-Carboxyfluorescein mixed isomers	Fluorescent Dyes/Probes
5(6)-Carboxyfluorescein (5(6)-FAM) is an amine-reactive pH-sensitive green fluorescent probe. 5(6)-Carboxyfluorescein (5(6)-FAM) can be used to label proteins, peptides and nucleotides. 5(6)-Carboxyfluorescein can be used for the detection of tumour areas in vivo .

HY-D2227

IR-58	Fluorescent Dyes/Probes
IR-58, a mitochondria-targeting near-infrared (NIR) fluorophore, is an autophagy enhancer. IR-58 kills tumour cells and induces apoptosis via inducing excessive autophagy, which is mediated through the reactive oxygen species (ROS)-Akt-mTOR pathway .

Cat. No.	Product Name	Type

HY-139109

IR-783 ADS 780WS	Indicators
IR-783 (ADS 780WS) is a near-infrared (NIR) heptamethine cyanine fluorescent probe. IR-783 significantly inhibits tumour growth and induces apoptosis in MDA-MB-231 xenograft model. IR-783 can be used to study breast cancer .

HY-159067

DEAE-dextran, MW 500000 hydrochloride

DEAE-dextran, MW 500000 (hydrochloride), from bacterial (Leuconostoc mesenteroides); Diethylaminoethyl-dextran, MW 500000 hydrochloride

Carbohydrates

DEAE-dextran, MW 500000 hydrochloride (DEAE-dextran, MW 500000 hydrochloride, from bacterial (Leuconostoc mesenteroides)) is a high-molecular-weight positively charged polymer that significantly enhances the uptake of viral RNA by tissue culture cells. When employed in the delivery system for "tumor immunity" RNA-splenocyte transfer, DEAE-dextran can markedly extend the lifespan of tumor-bearing animals, comparable to that of actively immunized animals. Furthermore, DEAE-dextran serves as a complexing agent for nucleic acids, forming composite particles with DNA/RNA for extensive applications in gene delivery. Additionally, DEAE-dextran can be utilized as a coating for liposomes .

Cat. No.	Product Name	Target	Research Area

HY-172320

BMS-986238	PD-1/PD-L1	Cancer
BMS-986238, a second-generation macrocyclic peptide, is a potent PD-L1 inhibitor. BMS-986238 has the potential for the study of solid tumours and lymphomas (cancer of the lymphatic system) .

HY-P0132

YIGSR Laminin Fragment 929-933	NO Synthase	Cancer
YIGSR is a peptide that can inhibit the tumour growth and metastasis of leukaemic cells . YIGSR blocks the cellular binding to laminin I via a 67-kDa laminin-binding protein, and inhibits shear-induced increase in eNOS expression of laminin cells .

HY-P2284

AD 01 1 Publications Verification	Transmembrane Glycoprotein	Cancer
AD 01, a 24 amino acid peptide of FKBPL (FK506-binding protein like), possesses potent anti-angiogenic activity. AD 01 bind to the CD44 receptor and inhibit tumour cell migration in a CD44 dependant manner .

HY-W014049

N'-Nitro-D-arginine 1 Publications Verification	NO Synthase	Others
N'-Nitro-D-arginine, a nitric oxide synthesis inhibitor, also is a vasodilator that relaxes the smooth muscles and increases blood flow to the penis, improving erections. N'-Nitro-D-arginine also inhibits neutrophil migration by blocking receptors for tumour necrosis factor alpha (TNFα) and interleukin 8 (IL8) .

HY-P5472

Tumour-associated MUC1 epitope	Transmembrane Glycoprotein	Others
Tumour-associated MUC1 epitope is a biological active peptide. (This sequence is the hallmark of MUC1 mucin. MUC1 is a highly glycosylated type I transmembrane glycoprotein with a unique extracellular domain consisting of a variable number of tandem repeats (VNTR) of this 20 amino acid peptide. It is overexpressed on the cell surface of many human adenocarcinomas and hematological malignancies, including multiple myeloma and B-cell lymphoma, making MUC1 broadly applicable target for immunotherapeutic strategies.)

HY-16215

Mipsagargin G-202	Peptide-Drug Conjugates (PDCs) PSMA Calcium Channel	Cancer
Mipsagargin (G-202) is a novel thapsigargin-based targeted proagent consisting of a prostate-specific membrane antigen (PSMA)-specific peptide coupled to an analog of the potent sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump inhibitor Thapsigargin (HY-13433). Mipsagargin is activated by PSMA-mediated cleavage of an inert masking peptide. Mipsagargin has the potential for refractory, advanced or metastatic solid tumours research .

HY-16498

Tigapotide PCK-3145	Apoptosis	Cancer
Tigapotide (PCK-3145) is an anti-tumour peptide that reduces the development of skeletal metastases associated with prostate cancer. Tigapotide induces apoptosis and reduces tumour parathyroid hormone-related peptide (PTHrP) levels .

HY-P10825

p21PBP	DNA/RNA Synthesis	Cancer
p21PBP, a 20 amino-acid peptide, is an inhibitor of DNA replication. p21PBP specifically binds to purified proliferating cell nuclear antigen (PCNA) in tumour cell extracts. p21PBP is promising for research of cancers .

HY-P5742

ELAAWCRWGFLLALLPPGIAG	EGFR	Cancer
ELAAWCRWGFLLALLPPGIAG (P5) is derived from rat HER2/neu protein with 21 amino acid length (aa 5-25). ELAAWCRWGFLLALLPPGIAG can induce cytotoxic T lymphocyte (CTL) responses in mice bearing HER2-positive tumours .

HY-P5742A

ELAAWCRWGFLLALLPPGIAG TFA	EGFR	Cancer
ELAAWCRWGFLLALLPPGIAG TFA (P5) is derived from rat HER2/neu protein with 21 amino acid length (aa 5-25). ELAAWCRWGFLLALLPPGIAG TFA can induce cytotoxic T lymphocyte (CTL) responses in mice bearing HER2-positive tumours .

HY-P10507

MART-1 nonamer antigen	Peptides	Cancer
MART-1 nonamer antigen (LAGIGILTV) is a melanoma antigen that can be recognized by T cells. MART-1 nonamer antigen behaves as a superagonist by in vitro inducing specific T cells with enhanced immunological functions. MART-1 nonamer antigen can be used as a model to design peptides for use in anti-tumour vaccines .

HY-13545B

ABT-510 acetate	Apoptosis	Inflammation/Immunology Cancer
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-13545

ABT-510	Apoptosis	Inflammation/Immunology Cancer
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-P0132A

YIGSR-Lys(N3)	NO Synthase	Cancer
YIGSR-Lys(N3) is a peptide that can inhibit the tumour growth and metastasis of leukaemic cells. YIGSR blocks the cellular binding to laminin I via a 67-kDa laminin-binding protein, and inhibits shear-induced increase in eNOS expression of laminin cells . YIGSR-Lys(N3) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Cat. No.	Product Name	Target	Research Area

HY-P99450

Avdoralimab IPH 5401; Anti-C5aR1 mAb	Complement System	Inflammation/Immunology Cancer
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .

HY-P99245

Emactuzumab RG 7155; RO 5509554	c-Fms	Cancer
Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with K_i value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) .

HY-P991349

GNR-051	PD-1/PD-L1	Cancer
GNR-051 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. GNR-051 can be used in Solid tumours research .

HY-P99565

Tengonermin ARENEGYR; NGR-TNF; NGR-hTNF	TNF Receptor	Cancer
Tengonermin (ARENEGYR) is a vascular-targeting agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. Tengonermin increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment .

HY-P991457

AVE1642	IGF-1R	Cancer
AVE1642 is a human IgG monoclonal antibody (mAb) targeting CD221/IGF1R. AVE1642 delays growth of tumour xenografts and prolongs the survival of tumour-bearing nude mice. AVE1642 can be used in advanced solid tumours research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991348

BAT-1306	PD-1/PD-L1	Cancer
BAT-1306 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. BAT-1306 can be used in Colorectal cancer and Solid tumours research .

HY-P991469

AMG-211 MEDI-565	Transmembrane Glycoprotein	Cancer
AMG-211 (MEDI-565) is a human monoclonal antibody (mAb) targeting CEACAM5/CEA/CD66e. AMG-211 can be used in Gastrointestinal cancer and Solid tumours research .

HY-P991344

AMP-224	PD-1/PD-L1	Cancer
AMP-224 is a fusion protein targeting PD-L2. AMP-224 specifically binds to PD-1 T cells (chronically stimulated/exhausted T cells). AMP-224 can be used in Colorectal cancer and Solid tumours research .

HY-P991391

COM902	Transmembrane Glycoprotein	Cancer
COM902 is a human IgG4 monoclonal antibody (mAb) targeting TIGIT. COM902 enhances anti-tumor immune responses. COM902 can be used in Multiple myeloma, Solid tumours and Colorectal cancer research. Recommended isotype control: IgG4-lambda .

HY-P991352

SG-001	PD-1/PD-L1	Cancer
SG-001 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. SG-001 can be used in Cervical cancer, Colorectal cancer, Solid tumours and Biliary cancer research .

HY-P9908

Adalimumab Maximum Cited Publications 9 Publications Verification Anti-Human TNF-alpha, Human Antibody	TNF Receptor Bacterial	Inflammation/Immunology Cancer
Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).

HY-P991438

XmAb-662	Interleukin Related	Cancer
XmAb-662 is a fusion protein targeting IL-12. XmAb-662 can be used in solid tumours research .

HY-P991390

BAT-6021	Transmembrane Glycoprotein	Cancer
BAT-6021 is a human monoclonal antibody (mAb) targeting TIGIT. BAT-6021 can be used in Solid tumours research .

HY-P99160

Labetuzumab	Transmembrane Glycoprotein	Cancer
Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy .

HY-P99617

Fianlimab REGN3767	LAG-3	Inflammation/Immunology Cancer
Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity .

HY-P99380

Zanidatamab 1 Publications Verification ZW 25	EGFR	Cancer
Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity .

HY-P99246

Bermekimab MABp1	Interleukin Related	Inflammation/Immunology Cancer
Bermekimab (MABp1) is a human monoclonal antibody that targets interleukin-1alpa (IL-1α). Bermekimab prevents tumour-related inflammation .

HY-P99675

Ivonescimab AK112	PD-1/PD-L1 VEGFR	Cancer
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL) .

HY-P991605

HLX26	LAG-3	Cancer
HLX26 is a humanised anti-LAG-3 monoclonal antibody. HLX26 has antitumor activity especially advanced solid tumours. HLX26 can be used for lymphoma research .

HY-P99895

Rulonilimab	PD-1/PD-L1	Inflammation/Immunology Cancer
Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .

HY-P991362

GB-223	TNF Receptor	Cancer
GB-223 is a human monoclonal antibody (mAb) targeting TNFSF11/RANKL/CD254. GB-223 can be used in Giant cell tumour of bone and Postmenopausal osteoporosis research .

HY-P9953

Certolizumab pegol 1 Publications Verification Certolizumab; CDP870	TNF Receptor	Inflammation/Immunology Cancer
Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research .

HY-P991357

STT-001	PD-1/PD-L1	Cancer
STT-001 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. STT-001 can be used in Solid tumours research .

HY-P991367

ES004	CD47	Cancer
ES004 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a. ES004 enhances macrophage phagocytosis and induces potent T cell responses to promote tumor killing. ES004 can be used in Solid tumours research .

HY-P99029

Magrolimab 2 Publications Verification Hu5F9-G4	CD47	Cancer
Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer .

HY-P99282

Citatuzumab bogatox VB6-845; Anti-Human EpCAM Recombinant Antibody Fab Fragment, 17-1A	Apoptosis	Cancer
Citatuzumab bogatox (VB6-845) is recombinant immunotoxin that composed of Fab fragment of humanized antibody targeting EpCAM and a modified cytotoxin bouganin. Citatuzumab bogatox binds to and selectively induces apoptosis in EpCAM-positive cell lines and shows good activity in EpCAM-positive human tumour xenograft models .

HY-P99618

Fidasimtamab IBI-315; BH2950	EGFR PD-1/PD-L1	Inflammation/Immunology Cancer
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity .

HY-P99379

Nidanilimab (Nadunolimab) CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)	Interleukin Related	Cancer
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a K_d value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .

HY-P99189

Cixutumumab IMC-A12; NSC742460	IGF-1R	Cancer
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer .

HY-P99176

ATG-031 2 Publications Verification	Inhibitory Antibodies	Cancer
ATG-031 is a humanized anti-CD24 monoclonal antibody with high affinity and specificity. ATG-031 interacts with Siglec-10 expressed by tumor-associated macrophages. ATG-031 effectively stimulates macrophage-mediated phagocytosis and induces cancer cell destruction by blocking the anti-phagocytic surface proteins. ATG-031 can be used in the study of haematological malignancies as well as solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P991354

GR-1405	PD-1/PD-L1	Cancer
GR-1405 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. GR-1405 enhances cytotoxic T lymphocyte (CTL)-mediated antitumor immune responses against PD-L1-expressing tumor cells. GR-1405 can be used in Lymphoma and Solid tumours research .

HY-P991455

PTX-35	TNF Receptor	Cancer
PTX-35 is a human IgG monoclonal antibody (mAb) targeting TNFRSF25. PTX-35 reduces the suppressive activity of regulatory T cells and enhances CD4+ T cell effector responses in a mouse melanoma model. PTX-35 can be used in Islet cell transplant rejection and Solid tumours research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99339

Tebentafusp IMCgp100	Interleukin Related TNF Receptor	Cancer
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour* cells .

HY-P991560

TQB-2928	CD47	Cancer
TQB-2928 is a monoclonal antibody against CD47, which can be used in the study of cancer.

HY-P99114

Sugemalimab	PD-1/PD-L1	Cancer
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .

HY-P99035

Naptumomab	Inhibitory Antibodies	Inflammation/Immunology Cancer
Naptumomab is a fusion protein of a tumor-targeting superantigen (TTS). Naptumomab stimulates the immune system to recognize and kill tumor cells and can be used in the study of refractory solid tumors such as renal cell carcinoma .

HY-P99011

Cibisatamab	CD3	Cancer
Cibisatamab, a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab can be used for colorectal cancer research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-17449

Fosbretabulin disodium CA 4DP; CA 4P; Combretastatin A4 disodium phosphate	Structural Classification other families Stilbenes Classification of Application Fields Source classification Plants Disease Research Fields Cancer	Microtubule/Tubulin Apoptosis
Fosbretabulin disodium (CA 4DP) is a tubulin destabilizing agent. Fosbretabulin disodium is the Combretastatin A4 proagent that selectively targets endothelial cells, induces regression of nascent tumour neovessels, reduces tumour blood flow and causes central tumour necrosis .

HY-N0570

Hydroxytyrosol 5+ Cited Publications DOPET; 3,4-Dihydroxyphenethyl alcohol; 3-Hydroxytyrosol	Infection Structural Classification Canarium album (Lour.) Rauesch. Classification of Application Fields Source classification Phenols Polyphenols Plants Endogenous metabolite Burseraceae Inflammation/Immunology Disease Research Fields	Endogenous Metabolite Bacterial Fungal
Hydroxytyrosol (DOPET) is a phenolic compound with anti-oxidant, anti-atherogenic, anti-thrombotic, antimicrobial, anti-inflammatory and anti-tumour effects .

HY-113136

1-Methylguanosine 2 Publications Verification N1-Methylguanosine	Infection Structural Classification Natural Products Other disease Classification of Application Fields Source classification Disease markers Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
1-Methylguanosine (N1-Methylguanosine) is a methylated nucleoside originating from RNA degradation. 1-Methylguanosine is a tumour marker .

HY-N0793

Protopine Corydinine	Alkaloids Structural Classification Corydalis yanhusuo W. T. Wang Classification of Application Fields Source classification Plants Isoquinoline Alkaloids Disease Research Fields Papaveraceae Cancer	Cholinesterase (ChE)
Protopine (Corydinine), an isoquinoline alkaloid, is a specific reversible and competitive inhibitor of acetylcholinesterase. Protopine exhibits anti-inflammation, anti-microbial, anti-angiogenic and anti-tumour activity .

HY-N8459

α-Cembrenediol α-CBD	Structural Classification Natural Products Nicotiana tabacum L. Source classification Plants Solanaceae	EBV
α-Cembrenediol is a potent inhibitor of EBV.α-Cembrenediol inhibits the early antigen of the Epstein-Bar virus. α-Cembrenediol also has anti-tumour activity .

HY-N3845

Ergosterol peroxide	Natural Products Classification of Application Fields Orchidaceae Source classification Plants Disease Research Fields Inflammation/Immunology Anoectochilus elwesii	Bacterial
Ergosterol peroxide is a steroid derivative and can be isolated from a variety of fungi, yeast, lichens or sponges. Ergosterol peroxide has anti-tumour, proapoptotic, anti-inflammatory, anti-mycobacterial, and anti-proliferative activities .

HY-N3797A

Echitamine chloride Ditaine chloride	Apocynaceae Alkaloids Structural Classification Classification of Application Fields Source classification Alstonia scholaris (L.) R. Br. Plants Disease Research Fields Indole Alkaloids Cancer	Apoptosis
Echitamine (Ditaine) chloride is the major monoterpene indole alkaloid present in Alstonia scholaris with potent anti-tumour activity. Echitamine chloride induces DNA fragmentation and cells apoptosis. Echitamine chloride inhibits pancreatic lipase with an IC₅₀ of 10.92 μM .

HY-N0793A

Protopine hydrochloride Corydinine hydrochloride	Structural Classification Alkaloids Other Alkaloids Source classification Rosaceae Pseudocydonia sinensis (Thouin) C. K. Schneid. Plants	Cholinesterase (ChE)
Protopine hydrochloride, an isoquinoline alkaloid, is a specific reversible and competitive inhibitor of acetylcholinesterase. Protopine hydrochloride exhibits anti-inflammation, anti-microbial, anti-angiogenic and anti-tumour activity .

HY-N14618

Rhodomycin A	Structural Classification Natural Products Microorganisms Source classification	Src
Rhodomycin A can suppress lung cancer cell progression via modulating Src-related pathways.?Rhodomycin A significantly suppressed cancer cell proliferation, migration, invasion, and clonogenicity in vitro and tumour growth in vivo .

HY-N0570R

Hydroxytyrosol (Standard) DOPET (Standard); 3,4-Dihydroxyphenethyl alcohol (Standard); 3-Hydroxytyrosol (Standard)	Structural Classification Canarium album (Lour.) Rauesch. Source classification Phenols Polyphenols Plants Endogenous metabolite Burseraceae	Reference Standards Endogenous Metabolite Bacterial Fungal
Hydroxytyrosol (Standard) is the analytical standard of Hydroxytyrosol. This product is intended for research and analytical applications. Hydroxytyrosol (DOPET) is a phenolic compound with anti-oxidant, anti-atherogenic, anti-thrombotic, antimicrobial, anti-inflammatory and anti-tumour effects .

HY-113136R

1-Methylguanosine (Standard)	Infection Structural Classification Natural Products Other disease Source classification Disease markers Endogenous metabolite Cancer	Endogenous Metabolite
1-Methylguanosine (Standard) is the analytical standard of 1-Methylguanosine. This product is intended for research and analytical applications. 1-Methylguanosine is a methylated nucleoside originating from RNA degradation. 1-Methylguanosine is a tumour marker .

HY-N7575

Lacto-N-fucopentaose II LNFP II	Structural Classification Polysaccharides Classification of Application Fields Source classification Disease markers Metabolic Disease Endogenous metabolite Disease Research Fields Saccharides Cancer	Endogenous Metabolite
Lacto-N-fucopentaose II (LNFP II) is a sialyl-Lewis, hapten of human Lewis bloodgroup determinant. Lacto-N-fucopentaose II monosialo-ganglioside/glycolipid and sialyl derivative, CA 19-9, is a molecular tumour markers (TM) for biliopancreatic malignancy .

HY-121370

a-D-Galactose	Structural Classification Human Gut Microbiota Metabolites Liliaceae Source classification Plants Endogenous metabolite Lilium davidii Duchartre ex Elwes Saccharides Monosaccharides	HIV Endogenous Metabolite
α-D-Galactose is a non-starch polysaccharide found in the bulb tissues of Lilium davidii var. unicolor Salisb. α-D-Galactose has anti-oxidation properties, anti-tumour activities, immunomodulatory effects and anti-HIV functions .

HY-N0793R

Protopine (Standard) Corydinine (Standard)	Alkaloids Structural Classification Corydalis yanhusuo W. T. Wang Source classification Plants Isoquinoline Alkaloids Papaveraceae	Reference Standards Cholinesterase (ChE)
Protopine (Standard) is the analytical standard of Protopine. This product is intended for research and analytical applications. Protopine (Corydinine), an isoquinoline alkaloid, is a specific reversible and competitive inhibitor of acetylcholinesterase. Protopine exhibits anti-inflammation, anti-microbial, anti-angiogenic and anti-tumour activity .

HY-125098

Illudin S 1 Publications Verification	Infection Microorganisms Classification of Application Fields Terpenoids Sesquiterpenes Source classification Disease Research Fields	DNA Alkylator/Crosslinker Apoptosis
Illudin S, a cytotoxic Illudin, is a natural sesquiterpene with strong anti-tumour and antiviral activities. Illudin S has genotoxic activities. Illudin S blocks the G1-S phase interface of the cell cycle in human leukemia cells .

HY-N12537A

(2R,3S)-PD-1/PD-L1-IN-38	Structural Classification Ketones, Aldehydes, Acids Labiatae Source classification Samanea saman (Jacq.) Merr. Plants	Aryl Hydrocarbon Receptor PD-1/PD-L1
(2R,3S)-PD-1/PD-L1-IN-38 (Compound (±)-13e) is an orally active Ah receptor (AhR) antagonist with in vivo and in vitro anticancer activity. (2R,3S)-PD-1/PD-L1-IN-38 promotes the secretion of INF-γ by CD8 ⁺T cells and inhibits the signal transduction of PD-1/PD-L1 .

HY-113604

Pentabromopseudilin	Structural Classification Natural Products Source classification Marine natural products Marine microorganism	TGF-β Receptor
Pentabromopseudilin (PBrP) is a marine antibiotic isolated from the marine bacteria Pseudomonas bromoutilis and Alteromonas luteoviolaceus. PBrP exhibits antimicrobial, anti-tumour and phytotoxic activities. PBrP is a reversible and allosteric inhibitor of myosin Va (MyoVa). PBrP also is a potent inhibitor of transforming growth factor-β (TGF-β) activity. PBrP can be used for the research of fibrotic diseases and cancer .

HY-W041470R

4-Methyl-1-phenyl-2-pentanone (Standard)	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite
Chlorpromazine (hydrochloride) (Standard) is the analytical standard of Chlorpromazine (hydrochloride). This product is intended for research and analytical applications. Chlorpromazine hydrochloride is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine hydrochloride exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine hydrochloride also blocks hNav1.7 channels (IC50=25.9 μM; concentration-dependent) and HERG potassium channels (IC50=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine hydrochloride also can inhibit clathrin-mediated endocytosis .

HY-N1377

Nevadensin Lysionotin	Structural Classification Flavonoids other families Classification of Application Fields Flavones Source classification Phenols Polyphenols Metabolic Disease Plants Inflammation/Immunology Disease Research Fields	Carboxylesterase (CES) DNA/RNA Synthesis Apoptosis Bacterial
Nevadensin (Lysionotin), a natural flavonoid, is a selective human carboxylesterase 1 (hCE1) inhibitor with an IC₅₀ of 2.64 μM. Nevadensin is more selective for hCE1 than hCE2 (IC₅₀ of 132.8 μM). Nevadensin can induce apoptosis and DNA damage in cancer cells. Nevadensin has a variety of pharmacological effects such as anti-inflammatory, anti-tumour, anti-hypertensive, anti-tubercular, antitussive, antioxidant and anti-microbial activities .

HY-N2447

Amarogentin 2 Publications Verification	Structural Classification Gentiana scabra Bunge Iridoids Classification of Application Fields Terpenoids Source classification Gentianaceae Phenols Polyphenols Metabolic Disease Plants Disease Research Fields	AMPK Apoptosis
Amarogentin is a secoiridoid glycoside that is mainly extracted from Swertia and Gentiana roots. Amarogentin exhibits many biological effects, including anti-oxidative, anti-tumour, and anti-diabetic activities. Amarogentin exerts hepatoprotective and immunomodulatory effects. Amarogentin promotes apoptosis, arrests G2/M cell cycle and downregulates of PI3K/Akt/mTOR signalling pathways. Amarogentin exerts beneficial vasculo-metabolic effect by activating AMPK .

HY-108016

Peruvoside Encordin	Apocynaceae Triterpenes Structural Classification Terpenoids Source classification Thevetia peruviana (Pers.) K. Schum. Plants	Src PI3K JNK STAT EGFR Apoptosis Autophagy
Peruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and EGFR. Peruvoside induces apoptosis and autophagy and possesses a broad spectrum of anticancer activity in breast, lung, liver cancers and leukemia. Peruvoside is a broad-spectrum and potent antiviral activity against positive-sense RNA viruses. Peruvoside sensitizes Gefitinib (HY-50895)-resistant tumour cells (A549, PC9/gef and H1975) to Gefitinib .

HY-N6682

Cytochalasin D Maximum Cited Publications 67 Publications Verification Zygosporin A; NSC 209835	Infection Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields	Arp2/3 Complex Antibiotic YAP
Cytochalasin D (Zygosporin A) is a potent actin polymerization inhibitor, could be derived from fungus. Cytochalasin D has cell-permeable activity. Cytochalasin D inhibits the G-actin–cofilin interaction by binding to G-actin. Cytochalasin D also inhibits the binding of cofilin to F-actin and decreases the rate of both actin polymerization and depolymerization in living cells. Cytochalasin D can reduce exosome release, in turn reducing the amount of survivin present in the tumour environment. Cytochalasin D induces phosphorylation and cytoplasmic retention of Yap .

HY-N2447R

Amarogentin (Standard)	Structural Classification Gentiana scabra Bunge Iridoids Terpenoids Source classification Gentianaceae Phenols Polyphenols Plants	Reference Standards AMPK Apoptosis
Amarogentin (Standard) is the analytical standard of Amarogentin. This product is intended for research and analytical applications. Amarogentin is a secoiridoid glycoside that is mainly extracted from Swertia and Gentiana roots. Amarogentin exhibits many biological effects, including anti-oxidative, anti-tumour, and anti-diabetic activities. Amarogentin exerts hepatoprotective and immunomodulatory effects. Amarogentin promotes apoptosis, arrests G2/M cell cycle and downregulates of PI3K/Akt/mTOR signalling pathways. Amarogentin exerts beneficial vasculo-metabolic effect by activating AMPK .

HY-N1377R

Nevadensin (Standard) Lysionotin (Standard)	Structural Classification Flavonoids other families Flavones Source classification Phenols Polyphenols Plants	Carboxylesterase (CES) Reference Standards DNA/RNA Synthesis Apoptosis Bacterial
Nevadensin (Standard) (Lysionotin (Standard)) is the analytical standard of Nevadensin (HY-N1377). This product is intended for research and analytical applications. Nevadensin, a natural flavonoid, is a selective human carboxylesterase 1 (hCE1) inhibitor with an IC₅₀ of 2.64 μM. Nevadensin is more selective for hCE1 than hCE2 (IC₅₀ of 132.8 μM). Nevadensin can induce apoptosis and DNA damage in cancer cells. Nevadensin has a variety of pharmacological effects such as anti-inflammatory, anti-tumour, anti-hypertensive, anti-tubercular, antitussive, antioxidant and anti-microbial activities.

HY-B0900R

Anethole (Standard)	Structural Classification Simple Phenylpropanols Leguminosae Source classification Phenylpropanoids Umbelliferae Plants Vernonia Schreb. Glycyrrhiza uralensis Fisch.	Apoptosis Fungal Bacterial MMP NF-κB
Anethole (Standard) is the analytical standard of Anethole. This product is intended for research and analytical applications. Anethole is a type of orally active aromatic compound that is widely found in nature and used as a flavoring agent. Anethole possesses anticancer, anti-inflammatory, antioxidant, antibacterial, antifungal, anesthetic, estrogenic, central nervous system depressant, hypnotic, insecticidal, and gastroprotective effects. Anethole can be used in the study of oxidative stress-related skin diseases and prostate cancer .

HY-B0900

Anethole 1 Publications Verification Anise camphor; p-Propenylanisole; Isoestragole	Structural Classification Classification of Application Fields Source classification Plants Microorganisms Simple Phenylpropanols Leguminosae Phenylpropanoids Umbelliferae Vernonia Schreb. Glycyrrhiza uralensis Fisch. Disease Research Fields Cancer	Apoptosis Fungal Bacterial MMP NF-κB
Anethole is a type of orally active aromatic compound that is widely found in nature and used as a flavoring agent. Anethole possesses anticancer, anti-inflammatory, antioxidant, antibacterial, antifungal, anesthetic, estrogenic, central nervous system depressant, hypnotic, insecticidal, and gastroprotective effects. Anethole can be used in the study of oxidative stress-related skin diseases and prostate cancer .

Cat. No.	Product Name	Chemical Structure

HY-N0570S

Hydroxytyrosol-d4
Hydroxytyrosol-d₄ is the deuterium labeled Hydroxytyrosol. Hydroxytyrosol (DOPET) is a phenolic compound drawn from the olive tree and its leaves with anti-oxidant, anti-atherogenic, anti-thrombotic, antimicrobial, anti-inflammatory and anti-tumour effects .

HY-B0448S

Phenytoin-d10
Phenytoin-d₁₀ is the deuterium labeled Phenytoin. Phenytoin (5,5-Diphenylhydantoin) is a potent Voltage-gated Na+ channels (VGSCs) blocker. Phenytoin has antiepileptic activity and reduces breast tumour growth and metastasis in mice .

HY-16293S

Lurbinectedin-d3
Lurbinectedin-d₃ is deuterium labeled Lurbinectedin. Lurbinectedin (PM01183) is a DNA minor groove covalent binder with potent anti-tumour activity; inhibits RMG1 and RMG2 cell growth with IC₅₀ values of 1.25 and 1.16 nM, respectively .

HY-113136S

1-Methylguanosine-d3
1-Methylguanosine-d₃ (N1-Methylguanosine-d₃) is deuterium labeled 1-Methylguanosine (HY-113136). 1-Methylguanosine is a methylated nucleoside originating from RNA degradation. 1-Methylguanosine is a tumour marker .

HY-13619S

Efaproxiral-d6
Efaproxiral-d₆ is the deuterium labeled Efaproxiral. Efaproxiral (RSR13) is a haemoglobin (Hb) synthetic allosteric modifier, decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy .

HY-N0570S1

Hydroxytyrosol-d5
Hydroxytyrosol-d₅ is the deuterium labeled Hydroxytyrosol. Hydroxytyrosol (DOPET) is a phenolic compound drawn from the olive tree and its leaves with anti-oxidant, anti-atherogenic, anti-thrombotic, antimicrobial, anti-inflammatory and anti-tumour effects .

HY-B0448S1

Phenytoin-15n2,13c
Phenytoin- ¹⁵N₂, ¹³C is the ¹³C and ¹⁵N labeled Phenytoin . Phenytoin (5,5-Diphenylhydantoin) is a potent Voltage-gated Na+ channels (VGSCs) blocker. Phenytoin has antiepileptic activity and reduces breast tumour growth and metastasis in mice .

HY-B0448S2

Phenytoin-d5
Phenytoin-d₅ (5,5-Diphenylhydantoin-d₅) is deuterium labeled Phenytoin. Phenytoin (5,5-Diphenylhydantoin) is a potent Voltage-gated Na ⁺ channels (VGSCs) blocker. Phenytoin has antiepileptic activity and reduces breast tumour growth and metastasis in mice .

HY-W768245

a-D-Galactose-1,2-13C2 1-phosphate potassium
a-D-Galactose-1,2- ¹³C₂ 1-phosphate potassium is the ¹³C- and ¹⁵N-labeled a-D-Galactose (HY-121370). α-D-Galactose is a non-starch polysaccharide found in the bulb tissues of Lilium davidii var. unicolor Salisb. α-D-Galactose has anti-oxidation properties, anti-tumour activities, immunomodulatory effects and anti-HIV functions .

HY-10211S

Tanespimycin-d5

Tanespimycin-d₅ (17-AAG-d₅; NSC 330507-d₅; CP 127374-d₅) is the deuterium labeled Tanespimycin (HY-10211). Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC₅₀ of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90 . Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression .

Cat. No.	Product Name		Classification

HY-14373

CB30865 ZM 242421		Alkynes
CB30865 (ZM 242421) is a nicotinamide phosphoribosyltransferase (Nampt) inhibitor, with potent cytotoxicity. CB30865 is highly potent against a variety of human tumour cell lines (IC₅₀ values in the 1-10 nM range) . CB30865 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14375

CB 300919		Alkynes
CB 300919 is a quinazoline-based antitumour agent with high activity in the CH1 human ovarian tumour xenograft. CB 300919 has a continuous exposure (96 h) growth inhibition IC₅₀ value of 2 nM in human CH1 ovarian tumor xenograft . CB 300919 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-159147

SIAIS039		Azide
SIAIS039 is an orally active c-ros oncogene 1 (ROS1)-specific PROTAC with DC₅₀s of 154.46 nM, 126.47 nM, 143.69 nM for HCC78 cells, Ba/F3 expressing the CD74-ROS1 fusion and Ba/F3 expressing the SDC4-ROS1 fusion, respectively. SIAIS039 suppresses cell proliferation, induces cell cycle arrest and apoptosis, and inhibits clonogenicity against ROS1-positive cells. SIAIS039 demonstrates anti-tumour effects against ROS1-driven tumor growth vivo. SIAIS039 is composed of the ALK inhibitor Brigatinib (HY-12857), a linker EM-12 (HY-138793), and a VHL ligand E3 ubiquitin ligase 1-Butyne (Red: Brigatinib; Blue: VHL ligand; Black: linker) .

Cat. No.	Product Name		Classification

HY-158829

SSOe26 sodium		Antisense Oligonucleotides
SSOe26 sodium is a 15mer antisense oligonucleotide targeting?HER4. SSOe26 sodium induces exon 26 skipping, leading to the generation of a novel mRNA transcript that excludes exon 26 (CYT2 isoform). SSOe26 sodium decreases tumour growth in mouse xenografts.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks